Breakout Ventures

The journey of bringing bio-based technologies from the lab to the market is anything but easy, and having a trusted guide can make all the difference.? ???? ?????? ???????????????? ???? ???????????????? ?????? ???????????????? ???? ???????? ?????? ?????????????? ???????????????? ???? ?????? ????????! These industry experts will support Breakout, our portfolio, and our broader ecosystem — from diligencing investment opportunities to commercializing new tech. ???????????? ???????? ???? ???? ??????????????????: ? Sridhar Iyengar, PhD: Founder and Chief Strategy Officer of Elemental Machines ? Coco Krumme, PhD: Founder of Leeward Co ? Rebecca Nugent, PhD: VP of HTP Operations at Tessera Therapeutics ? Walter Solomon: Board Director and Advisor ? Ilan Zipkin, PhD: Founder and CEO of Supercede Therapeutics, Inc. Breakout Ventures is built on the theory that creative bioscience founders need more than just capital to take on the world's biggest challenges in human health and sustainability. Thank you to our venture partners, advisors, and community members for helping us build a bio-based future! ???????? ?????? ???????? ??????????????: https://lnkd.in/gp4SADTe

To stop sepsis in its tracks, a great nurse makes all the difference. Congratulations to Cytovale on their team's new addition, Chief Nursing Officer Rhonda Collins. ???????? ???? ?? ????????????: Sepsis is a life-threatening condition—and the third leading cause of death in US hospitals—with the risk of death increasing by 8% every hour it goes untreated. Cytovale’s rapid sepsis detection platform, IntelliSep?, reduces risk-adjusted mortality by 30% when used in nurse-driven sepsis protocols. Having spent decades advocating for patient safety and innovation in healthtech, Rhonda Collins, DNP, RN, FAAN is the perfect person to help emergency department nurses across the country implement Cytovale's life-saving technology. ???????? ?????? ???????? ??????????????:https://lnkd.in/dDKnzuAJ

Congratulations to Surf Bio for welcoming Doug Hecker as their new Head of Technical Operations to advance high-concentration biologic drug delivery. ???????? ???? ?? ????????????: Surf Bio's SnapShot? platform enables high-dose biologics to be administered via subcutaneous injection, enhancing accessibility and convenience for patients. Doug Hecker is joining Surf Bio with 30+ years of experience in CMC, drug manufacturing, and regulatory compliance - he notably played a key role in bringing drug solubility & stability optimizing compound Captisol? to market. Per Surf Bio CEO, Bryan Mazlish, "Doug's leadership will be instrumental in scaling the SnapShot platform, accelerating our path to clinical studies, and deepening commercial collaborations with leading biopharmaceutical companies." ???????? ?????? ???????? ??????????????: https://lnkd.in/g2BdK_QM #Biopharma #Biologics #DrugDelivery #LifeSciences #Innovation

Phantom Neuro believes losing mobility shouldn’t mean losing independence—and the FDA agrees. Congrats to the team on securing breakthrough device and Targeted Acceleration Pathway (TAP) designations! ???????? ???? ?? ???????????? ? ?? Phantom X, a minimally invasive neural interface that provides intuitive control of prosthetics and robotic devices, has earned both FDA breakthrough and TAP designations. These designations allow Phantom Neuro to accelerate regulatory and clinical processes to reach patients sooner. ?? Phantom Neuro's cutting-edge technology deciphers natural human motion, offering intuitive control of prosthetics. In a recent study, Phantom X achieved 94% accuracy in decoding real-time gestures across 11 essential hand and wrist movements. ?? The device is implanted just beneath the skin in an outpatient procedure, making it accessible to over 70,000 surgeons. The platform’s algorithms can then decode natural human movement, offering near-human control over prosthetics. ???????? ?????? ???????? ???????? ???? MassDevice ???????? Danielle Kirsh: https://lnkd.in/diWuSJEf

Under the leadership of its new CEO, John Krzywicki, Checkerspot is doubling down on eco-friendly fats and oils. ???????? ???? ?? ????????????: ?? Microalgae, nature’s original oil producer, is at the heart of Checkerspot’s sustainable approach to creating high-value fats with a lower carbon footprint. ?? Thanks to Checkerspot's platform technology, food manufacturers can create resilient supply chains and reduce reliance on unsustainable sources like palm and coconut oil ?? Ongoing partnerships with industry leaders like AAK and Mara Renewables CORP are accelerating adoption of sustainable, high-performance ingredients. Per John, “The market is clearly asking for our solutions and we’re orienting our business to be hyper-efficient in providing them.” ???????? ?????? ???????? Food-Navigator ??????????: https://lnkd.in/gtFCJpNX

Heading to Austin4America next week? Be sure to check out "Stretching Beyond the Physical: Intersection of Tech and Quality of Life” with Phantom Neuro CEO and Founder Connor Glass! Learn more and register for the conference: https://lnkd.in/gsiTHmvw

140 industry experts weighed in on which major therapeutic advancements to look out for in 2025. Check out what Surf Bio's Co-founder and CEO, Bryan Mazlish, had to say on Citeline's Scrip Asks. ?????????? ???? ?? ????????????: ?? Biologics are booming: The market has grown tenfold in the past decade and is poised for another tenfold expansion. ?? IV infusion bottleneck: The rapid growth of biologics is outpacing available infusion resources, making treatment access a critical issue. ?? The shift to subcutaneous delivery: Enabling self-administered, high-dose subcutaneous therapies is the key to staying competitive. ???????? ?????? ???????? ?????????????? ???? Eleanor Malone: https://lnkd.in/dNhMPMZi

Universities sit at the crossroads of groundbreaking innovation, charged with bridging the gap between research and commercialization. It's a big lift—but they don't have to do it alone! If you're attending next week's?AUTM Annual Meeting, be sure to check out "Getting More Than Just Capital from Your VC Relationships" on Tuesday, March 4. Our Director of Platform,?Susanna Harris, PhD, will be speaking alongside?Alex Turo (Rutgers Research), Mitra Miri (Osage University Partners (OUP)), and?Scott Alpizar (Emerging Innovations Consulting). ?????????????? ???? ?? ????????????: ?? Explore how universities can benefit from VC networks, expertise, and resources beyond financial investment. ?? Learn key strategies for fostering successful partnerships between academic innovators and venture firms. ?? Discover ways to identify opportunities and navigate common challenges in university-VC collaboration. See you there!

The path to get new medicines from discovery to commercialization is notoriously long and difficult—and it could get even harder with federal funding cuts. Will our industry rise to the challenge? Thank you to Gwendolyn Wu for diving into the question on everybody's mind. Check out the BioPharma Dive article to get the inside scoop from our Managing Partner, Lindy Morris Fishburne, as well as Christiana Bardon M.D. (MPM BioImpact), David K. Yang (Lux Capital), and Michelle Burbea Hoffmann (Chicago Biomedical Consortium). Oh, and to answer our own question: Absolutely yes. The people who make up the world of biotech are creative, resourceful, and resilient. Nobody said it would be easy, but that's never stopped us before. https://lnkd.in/eM9EiW7F

Was glad to add my thoughts on the ways we may need to backfill the loss of federal grant dollars - there is an important role for philanthropy/foundations to play to keep basic science advancing - thanks?Gwendolyn Wu?for the opportunity to discuss how changes to?NIH funding could impact long-term?innovation Read at BioPharma Dive?:?https://lnkd.in/gQ3TabBJ